What's Trending

Recent tariff increases are not only disrupting beauty brands’ supply chains and pricing strategies—they're also amplifying legal risks...

A major Federal Circuit ruling just sent a clear message to AI-driven healthtech companies: AI alone won’t get you a patent. In AliveCor,...

In Actavis v. U.S., a case at the intersection of tax law and patent law, the Federal Circuit held that generic drug companies’...

On February 28, 2025, the United States Patent and Trademark Office (USPTO) rescinded a June 2022 memorandum clarifying when the Patent...

Underscoring the exceptional value of a firm that’s purpose-built for tech and life sciences, Law360 named Fenwick a 2024 Practice Group...

Charlotte Tilbury is responding to the growing trend of beauty copycats, or dupes, with a sharp focus on marketing.  Last month,...

U.S. Patent and Trademark Office Director Kathi Vidal announced her departure from the agency to return to the private sector, a move...

The U.S. Patent and Trademark Office director, Kathi Vidal, released a final rule on Director Review effective October 31, which expands...

The United States Patent and Trademark Office (USPTO) has announced new rules governing amendment practice in trial proceedings under the...

In patent litigation, expert witnesses play a crucial role in providing specialized knowledge to the court. In a recent case where Osseo...

The recent case involving United Therapeutics' patent on Tyvaso and Liquidia's Yutrepia sheds light on the complexities of patent law....

Recent cases show the U.S. Patent and Trademark Office director's interest in using director review to address substantive issues like...